Resverlogix Corp. J (TSE:RVX)
TSX:RVX
Want to see TSE:RVX full AI Analyst Report?
Top Page
Resverlogix
(TSX:RVX)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.10
▲(1.00% Upside)
Action:N/A
Date:04/13/26
The score is primarily constrained by very weak financial performance (no revenue, sustained losses and cash burn, and negative equity with heavy leverage). Technicals provide only a modest offset due to mixed signals and negative momentum indicators, while valuation remains challenged because the company is loss-making and offers no dividend yield.
Positive Factors
Focused epigenetic pipeline
A clear scientific focus on epigenetic mechanisms and BET proteins gives Resverlogix a differentiated research thesis within cardiovascular and metabolic disease. This concentrated R&D strategy supports deeper expertise, clearer go-to-market options, and makes the company a more defined partner candidate for larger biopharma alliances over months.
Negative Factors
No operating revenue
Absence of revenue means all operations rely on financing or one-time events rather than product sales. This structurally increases execution risk, forces ongoing capital raises to fund R&D, and leaves the firm exposed to financing market cycles and dilution over the next 2–6 months absent a partnering or licensing deal.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused epigenetic pipeline
A clear scientific focus on epigenetic mechanisms and BET proteins gives Resverlogix a differentiated research thesis within cardiovascular and metabolic disease. This concentrated R&D strategy supports deeper expertise, clearer go-to-market options, and makes the company a more defined partner candidate for larger biopharma alliances over months.
Read all positive factors
Resverlogix (RVX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$34.38M
Dividend YieldN/A
Average Volume (3M)37.18K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth58.17%
CountryCA
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding343,841,700
10 Day Avg. Volume62,041
30 Day Avg. Volume37,183
Financial Highlights & Ratios
PEG Ratio-7.25
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resverlogix Business Overview & Revenue Model
Company Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor tha...
How the Company Makes Money
null...
Resverlogix Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2022 | Mar 2022 | Jul 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -437.53K | -476.75K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.77M | -4.25M | -11.74M | -14.87M | ― |
| Net Income | -7.90M | -7.63M | -3.61M | -24.77M | ― |
Balance Sheet | |||||
| Total Assets | 7.93M | 7.34M | 8.12M | 9.98M | 10.71K |
| Cash, Cash Equivalents and Short-Term Investments | 107.80K | 99.00K | 40.00K | 6.00K | 87.00 |
| Total Debt | 72.77M | 81.97M | 6.49M | 7.04M | 0.00 |
| Total Liabilities | 96.73M | 89.08M | 67.40M | 69.85M | 50.60K |
| Stockholders Equity | -88.80M | -81.73M | -59.28M | -59.87M | -94.90K |
Cash Flow | |||||
| Free Cash Flow | -3.73M | -4.36M | -3.99M | -8.90M | -4.41K |
| Operating Cash Flow | -3.73M | -3.89M | -3.54M | -8.02M | -4.40K |
| Investing Cash Flow | -660.36K | -377.00K | -473.00K | -833.00K | -426.00 |
| Financing Cash Flow | 4.39M | 4.36M | 4.06M | 8.81M | 4.95K |
Resverlogix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$37.41M | -6.54 | -8.01% | ― | -34.81% | -453.45% | |
46 Neutral | C$32.70M | -0.31 | -221.75% | ― | ― | 44.28% | |
45 Neutral | C$4.40M | -1.15 | -111.11% | ― | ― | -79.26% | |
42 Neutral | C$34.38M | -3.33 | 7.84% | ― | ― | 58.17% |
* Healthcare Sector Average
TSE:RVX
Resverlogix
0.10
0.06
122.22%
TSE:XRTX
XORTX Therapeutics Inc
3.16
-3.24
-50.62%
TSE:BCT
BriaCell Therapeutics
4.56
-42.84
-90.38%
TSE:MBX
Microbix Biosystms
0.27
-0.07
-20.59%
TSE:GSD
Devonian Health Group
11.15
1.85
19.89%
TSE:TTI
Thiogenesis Therapeutics Corp
0.60
-0.11
-15.49%
Resverlogix Corporate Events
Financial DisclosuresLegal ProceedingsRegulatory Filings and Compliance
Resverlogix Hit With Management Cease Trade Order Over Late Annual Filings
Negative
Apr 2, 2026
Resverlogix Corp. has received a management cease trade order from the Alberta Securities Commission after missing the March 31 deadline to file its 2025 annual financial statements and related disclosures. The order restricts trading in the compa...
Financial DisclosuresLegal ProceedingsRegulatory Filings and Compliance
Resverlogix Faces Filing Delay as Alberta Regulator Reviews Cease Trade Request
Negative
Apr 1, 2026
Resverlogix Corp. has confirmed it will miss the March 31, 2026 deadline to file its annual audited financial statements and related disclosures for the year ended December 31, 2025, due to delays in starting the audit process. The company and its...
Financial DisclosuresRegulatory Filings and Compliance
Resverlogix Faces Audit Delay and Seeks Management Cease Trade Order
Negative
Mar 18, 2026
Resverlogix Corp. has announced it will miss the March 31, 2026 deadline to file its annual audited financial statements, annual information form, and management discussion and analysis for the year ended December 31, 2025 due to delays in complet...
Business Operations and StrategyPrivate Placements and Financing
Resverlogix Converts $2.8 Million Interest into Equity in Insider-led Financing
Positive
Feb 19, 2026
Resverlogix Corp. has completed a CAD$2.8 million shares-for-interest private placement with an immediate family member of its Chairman and CEO, who subscribed for 28,000,000 common shares at CAD$0.10 each. Following the deal, the investor holds a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.